Curated News
By: NewsRamp Editorial Staff
April 29, 2025
Soligenix Advances Phase 3 Study of HyBryte(TM) for CTCL Treatment
TLDR
- Soligenix (NASDAQ: SNGX) advances phase 3 study for HyBryte(TM), a noninvasive therapy targeting malignant T-cells with precision.
- HyBryte(TM) utilizes synthetic hypericin activated by visible light to treat early-stage cutaneous T-cell lymphoma with potential regulatory agency approval.
- HyBryte(TM) offers a well-tolerated, innovative approach to tackle rare diseases, potentially improving treatment outcomes for patients worldwide.
- Soligenix's HyBryte(TM) study introduces a game-changing therapy using safe visible light to target malignant T-cells effectively.
Impact - Why it Matters
This news matters as it highlights the groundbreaking advancements in photodynamic therapy for treating CTCL, a rare disease. Soligenix's innovative approach with HyBryte(TM) showcases the potential for noninvasive, precise treatments that could revolutionize the field. Patients with CTCL and other skin-related conditions may benefit from the development of such therapies, indicating a significant step forward in the medical landscape.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is advancing its phase 3 replication study (“FLASH2”) for HyBryte(TM), a novel photodynamic therapy designed to treat early-stage cutaneous T-cell lymphoma (“CTCL”). Building on the success of a prior phase 3 trial, HyBryte(TM) offers a potentially game-changing approach by providing a noninvasive, well-tolerated alternative that targets malignant T-cells with precision. With patient enrollment underway and interim analysis expected in early 2026, the study is designed to potentially meet the stringent requirements of regulatory agencies to strengthen the case for HyBryte(TM) as a commercially available treatment. This milestone emphasizes Soligenix’s broader strategy of using innovative therapeutic approaches to tackle rare and difficult-to-treat diseases. The progress of HyBryte(TM) also underscores the importance of photodynamic therapy as a new and effective modality that could potentially be applied to other dermatological and oncological conditions.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Soligenix Advances Phase 3 Study of HyBryte(TM) for CTCL Treatment
